4 completed, 1 terminated, 1 unknown, 1 withdrawn. 3 Not applicable, 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 3 | Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 2 | Completed 2 |
Follow Lung Carcinoid Tumor: new trials by email Literature Review of Lung Carcinoid Tumor trials Research Report on Lung Carcinoid Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Physical Activity Intervention Before and After Surgery in Older Adults With Lung Cancer and Their Family Caregivers E-mail, Exercise Intervention, Quality-of-Life Assessment - Caregiver, Lobectomy Patient | Not applicable | Withdrawn | City of Hope Medical Center | 2021-05-15 | 2021-08-12 | |
| Bronchoscopic Laser Ablation of Peripheral Lung Tumors Cone-Beam Computed Tomography, Conventional Surgery, Laser Ablation - Lung Carcinoid Tumor, Lung Non-Small Cell Carcinoma | Not applicable | Terminated | M.D. Anderson Cancer Center | 4 | 2018-09-18 | 2023-02-16 |
| Active Surveillance in Early Lung Cancer Active Surveillance - Stage IA Non-small Cell Lung Cancer, Lung Carcinoid Tumor | Not applicable | Unknown | University of Vermont Medical Center | 26 | 2018-07-31 | 2020-07-16 |
| Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Laboratory Biomarker Analysis, Pharmacological Study, Temsirolimus - Adult Solid Neoplasm, Lung Carcinoid Tumor | Phase 1 | Completed | National Cancer Institute (NCI) | 21 | 2012-03-01 | 2015-10-06 |
| Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Cixutumumab, Everolimus, Laboratory Biomarker Analysis - Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor | Phase 1 | Completed | National Cancer Institute (NCI) | 27 | 2010-10-01 | 2016-07-15 |
| Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Bevacizumab, Temsirolimus - Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 252 | 2009-09-08 | 2019-01-25 |
| Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer Laboratory Biomarker Analysis, Pazopanib Hydrochloride, Pharmacological Study - Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor | Phase 2 | Completed | National Cancer Institute (NCI) | 52 | 2007-03-01 | 2020-04-03 |
Carcinoma, Non-Small-Cell Lung (3) · Somatostatinoma (3) · Glucagonoma (2) · Insulinoma (2) · Lung Neoplasms (2) · Zollinger-Ellison Syndrome (2) · Carcinoma, Hepatocellular (1) · Carcinoma, Medullary (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Renal Cell (1) · Fallopian Tube Neoplasms (1) · Motor Activity (1) · Multiple Endocrine Neoplasia Type 1 (1) · Ovarian Neoplasms (1) · Paraganglioma (1)
Neoplasms (7) · Neoplasms by Site (7) · Adenocarcinoma (4) · Carcinoma (4) · Neoplasms by Histologic Type (4) · Neoplasms, Glandular and Epithelial (4) · Bronchial Neoplasms (3) · Carcinoma, Bronchogenic (3) · Carcinoma, Islet Cell (3) · Carcinoma, Neuroendocrine (3) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Endocrine Gland Neoplasms (3) · Endocrine System Diseases (3) · Lung Diseases (3)
Sirolimus (2) · temsirolimus (2) · Acetates (1) · Bevacizumab (1) · Communication Devices for People with Disabilities (1) · Disulfides (1) · Everolimus (1) · Immunoglobulin G (1) · Laser Therapy (1) · Octreotide (1) · Salts (1) · Watchful Waiting (1) · cixutumumab (1) · pazopanib (1) · trebananib (1)
National Cancer Institute (NCI) (4) · City of Hope Medical Center (1) · M.D. Anderson Cancer Center (1) · University of Vermont Medical Center (1)
United States (5) · Canada (2)
James Yao (2) · Henry Pitot (1) · Philippe Bedard (1) · Roberto F Casal (1) · Virginia Sun (1)
PMID 25318437, PMID 25488966, PMID 25900182, PMID 25956795, PMID 37702588
P30CA016672 (2), N01CM00032 (1), N01CM00038 (1), N01CM00039 (1), N01CM00070 (1), N01CM00071 (1), N01CM00099 (1), N01CM00100 (1), N01CM62201 (1), N01CM62202 (1), N01CM62203 (1), N01CM62204 (1), N01CM62205 (1), N01CM62206 (1), N01CM62207 (1)